CJC-1295 DAC vs No DAC China Supplier Guide

Make DAC status a mandatory identity field

Create separate RFQ lines for CJC-1295 with DAC and the exact no-DAC material. State the full controlled name, sequence or molecular reference, DAC or conjugation status, termini and modifications where applicable, form, target purity, strength, quantity and Research Use Only status. Never accept a quotation that says only CJC-1295. Require the supplier to map its internal code to the quote, COA, analytical sample, vial label and packing list. Any change in DAC status requires a new technical review.

Resolve no-DAC and modified GRF naming

Ask the supplier to define precisely what it means by CJC-1295 without DAC, no DAC, Mod GRF 1-29 or modified GRF 1-29. Marketplace usage is not always consistent, so the approved sequence and molecular reference must control. Reconcile expected molecular information, abbreviation, salt or counterion and product code across all files. A category label, cap color or seller assurance is not enough. Keep unresolved naming differences as exceptions and do not infer equivalence from commonly used search terms.

Compare 2mg, 5mg and 10mg configurations

The catalog includes with-DAC 2mg and 5mg products and no-DAC 2mg, 5mg and 10mg products. Build a matrix showing molecular form, strength, vial count, units per kit, total nominal material, fill tolerance, parent lot, finished lot and price basis. Overlapping strengths create a high swap risk. Require distinct full-name labels and prohibit substitutions between forms or strengths. Compare total documented material and evidence scope rather than relying on vial or kit price.

Require form-specific HPLC and MS evidence

Review separate identity and chromatographic-purity packages for each exact molecular form and lot. Check expected and observed molecular information, sample identifier, complete chromatogram, integration, method reference, dates, report number and authorization. A with-DAC report cannot qualify a no-DAC lot, and an ambiguous CJC-1295 certificate should not be accepted. Confirm that the analytical sample connects to the parent and finished lots. HPLC purity does not independently prove DAC status or vial content.

Prevent mixed-order label and warehouse errors

Approve labels showing the full controlled material, DAC status, strength, lot and RUO wording. For orders containing both forms, require segregated packaging or a packing list organized by form, strength and lot. Ask how line clearance, label issuance, filling reconciliation, warehouse picking and final checks prevent swaps. Receiving staff should inspect representative labels, seals and lot codes. Quarantine any abbreviation, DAC status, strength or lot mismatch until a documented investigation and buyer decision are complete.

Build one comparable wholesale RFQ matrix

Send every candidate the same fields: controlled identity, strength, vial count, total material, target purity or composition, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, MOQ, lead time and shipping term. Mark missing answers as exceptions instead of filling gaps with assumptions. Separate testing, setup, customization and transport costs from recurring unit price. A standardized matrix gives scientific, purchasing and quality reviewers one auditable record and prevents an incomplete offer from appearing cheaper simply because it describes less work.

Apply a batch-focused quality-control review

Define every required attribute, acceptance criterion, method and record before purchase. Use the quality-control framework to connect each supplier claim to evidence and its method scope. Check sample identifiers, dates, report numbers, units and lot relationships across the complete reports. Batch-specific evidence is more decision-useful than a representative certificate. Preserve original files, record revisions and investigate contradictions before approving shipment. Where risk warrants, arrange independent testing under a documented sampling and custody plan.

Create a documentation gate before dispatch

List the required batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ and purchase order. Reconcile product, strength, lot, quantity and revision across records with the documentation guide. Require replacement documents when the offered lot changes. The importer remains responsible for current destination requirements. Research-use wording improves clarity but cannot guarantee customs entry or replace destination-specific legal and broker review.

Verify supplier and batch ownership

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A trading or coordination company can work with qualified partners, but roles and accountability must be transparent. Ask who owns the batch record, authorizes release, handles deviations and provides corrective action. Require advance notification when a critical party changes. Business-registration evidence supports identity but does not replace technical qualification of the offered lot.

Plan logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject guarantees of customs clearance or misleading declarations. On receipt, document package condition, seals, product, strength, lot and quantity, then connect internal inventory to the supplier batch. Store according to the applicable approved specification and quarantine unexplained damage, label conflicts, quantity differences or excursions until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification and evidence expectations planned for wholesale scale. Assess document accuracy, packaging, delivery time, communication and corrective response. Update a supplier scorecard from observed performance rather than catalog breadth or claims. For every new lot, repeat the batch review and approve current documents before dispatch. Require notification before changes to material specification, manufacturing, testing, filling, labels, packaging or other buyer-approved conditions.

Related products and same-category guides

• CJC-1295 with DAC 2mg
• CJC-1295 with DAC 5mg
• CJC-1295 without DAC 2mg
• CJC-1295 without DAC 5mg
• CJC-1295 without DAC 10mg
• CJC-1295 + Ipamorelin Guide
• Hexarelin vs Ipamorelin Guide

Frequently asked questions